The CFC to HFA transition and its impact on pulmonary drug development

Respiratory Care

Volumn 50, Issue 9, 2005, Pages 1201-1206

  Leach, Chet L ^a  

^a LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

Author keywords

CFC; Chlorofluorocarbon; DPI; Dry powder inhaler; HFA; Hydrofluoroalkane; MDI; Metered dose inhaler; Montreal Protocol; Ozone

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHLOROFLUOROCARBON; CICLESONIDE; FLUNISOLIDE; FLUORINATED HYDROCARBON; FLUTICASONE; OZONE; PROPELLANT; SALBUTAMOL SULFATE; STEROID; TRIAMCINOLONE; RESPIRATORY TRACT AGENT;

AIRWAY; ASTHMA; CANDIDIASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG DELIVERY SYSTEM; DRUG FORMULARY; DRUG INDUSTRY; DRUG TARGETING; DRY POWDER; GREENHOUSE EFFECT; HEALTH CARE; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; METERED DOSE INHALER; NONHUMAN; OZONE LAYER; PATIENT SAFETY; RESPIRATORY TRACT DISEASE; RHINITIS; THRUSH; TREATMENT OUTCOME; AIR POLLUTION; INHALATIONAL DRUG ADMINISTRATION; INTERNATIONAL COOPERATION; LEGAL ASPECT; MASS COMMUNICATION; PHARMACEUTICS; POWDER; REVIEW;

ADMINISTRATION, INHALATION; AEROSOL PROPELLANTS; AIR POLLUTION; CHLOROFLUOROCARBONS; DIFFUSION OF INNOVATION; HUMANS; HYDROCARBONS, FLUORINATED; INTERNATIONALITY; METERED DOSE INHALERS; OZONE; POWDERS; RESPIRATORY SYSTEM AGENTS; TECHNOLOGY, PHARMACEUTICAL;

EID: 33644621503     PISSN: 00201324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (21)

1. Leach CL. Approaches and challenges to use Freon propellant replacements. Aerosol Sci Technol 1995;22(4):328-334.
2. The Montreal Protocol on substances that deplete the ozone layer. Final Act (Nairobi: UNEP1987). Federal Register 1994;59 FR 56276-56298.
3. Alexander DJ. Safety of propellants. J Aerosol Med 1995;8 Suppl 1:S41-S47.
4. Gabrio BJ, Stein SW, Velasquez D. A new method to evaluate plume characteristics of hydrofluoroalkane and chlorofluorocarbon metered dose inhalers. Int J Pharm 1999;186(1):3-12.
5. Manzer LE. The CFC-ozone issue: progress on the development of alternatives to CFCs. Science 1990;249(4964):31-35.
6. Porter G. Chlorine-an introduction. Pure Appl Chem 1996;68(9): 1683-1687. http://www.iupac.org/publications/pac/1996/pdf/ 6809x1683.pdf. Accessed June 24, 2005.
7. Hayman G. Why the environment matters. Br J Clin Pract 1995; 49(75):2-6.
8. Molina MJ, Rowland FS. Stratospheric sink for chlorofluoromethanes: chlorine atom-catalysed destruction of ozone. Nature 1974; 249(5460):810-812.
9. International Pharmaceutical Aerosol Consortium for Toxicity Testing (IPACT-1), data on file. Drug Master File 9857, 9859.
10. Leach CL. Toxicology of propellants. In: TS Purewal, DJ Grant, editors. Metered dose inhaler technology. Buffalo Grove, Illinois: Interpharm Press; 1998:229-254.
11. Tansey I. The technical transition to CFC-free inhalers. Br J Clin Pract Suppl 1997;89:22-27.
12. Leach CL. Safety assessment of the HFA propellant and the new inhaler (Airomir). Eur Res Rev 1997;7(41):35-38.
13. US Food and Drug Administration. Advance notice of proposed rule making on chlorofluorocarbon propellants in self-pressurized containers: determination that uses are no longer essential. National Press Office; 1997. 62 Fed Reg 10242 (March 6, 1997).
14. Hamid Q, Song Y, Kotsimbos TC, Minshall E, Bai TR, Hegele RG, Hogg JC. Inflammation of small airways in asthma. J Allergy Clin Immunol 1997;100(1):44-51.
15. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered dose inhaler compared with CFC-beclomethasone. Eur Res J 1998;12(6):1346-1353.
16. Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Lung deposition of HFA-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest 2002;122(2):510-516.
17. Shaw NJ, Edmonds AT. Inhaled beclomethasone and oral candidiasis. Arch Dis Child 1986;61(8):788-790.
18. Leach CL. Relevance of radiolabeled steroid inhalation studies to clinical outcomes. J Aerosol Med 1998;11 Suppl 1:S29-S34.
19. Busse WW, Brazinsky S, Jacobson K, Stricker W, Schmitt K, Vanden Burgt J, et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 1999;104(6): 1215-1222.
20. Dolovich M, Leach CL. Drug delivery devices and propellants. In: WW Busse, ST Holgate, editors. Asthma and Rhinitis, 2nd ed. Boston: Blackwell Scientific; 2000:1719-1731.
21. Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines. Chest 2005;127(1):335-371.